Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,829 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Optimal timing for initiating androgen receptor signaling inhibitor therapy in patients with nonmetastatic castration-resistant prostate cancer: a multicenter collaborative study.
Hara S, Urabe F, Tashiro K, Goto Y, Iwamoto Y, Ohtsuka T, Fukuokaya W, Imai Y, Iwatani K, Atsuta M, Mori K, Igarashi T, Aikawa K, Yanagisawa T, Kimura S, Murakami M, Tsuzuki S, Yanada BA, Hata K, Furuta A, Yamada H, Miki J, Kimura T; JIKEI-YAYOI Collaborative Group. Hara S, et al. Among authors: murakami m. Jpn J Clin Oncol. 2024 Oct 19:hyae146. doi: 10.1093/jjco/hyae146. Online ahead of print. Jpn J Clin Oncol. 2024. PMID: 39426804
Prognostic model with alkaline phosphatase, lactate dehydrogenase and presence of Gleason pattern 5 for worse overall survival in low-risk metastatic hormone-sensitive prostate cancer.
Tsuzuki S, Kawano S, Fukuokaya W, Mori K, Nishikawa H, Tashiro K, Watanabe D, Uchimoto T, Nishimura K, Yano Y, Murakami M, Koike Y, Hata K, Koide H, Miki J, Abe H, Yamada H, Naruoka T, Sugaya S, Kimura T, Tomita M, Nakajo H, Egawa S. Tsuzuki S, et al. Among authors: murakami m. Jpn J Clin Oncol. 2021 Nov 1;51(11):1665-1671. doi: 10.1093/jjco/hyab115. Jpn J Clin Oncol. 2021. PMID: 34296282
Survival outcome of chemotherapy-naïve castration-resistant prostate cancer treated with new-generation androgen receptor axis-targeted agents in real-world analysis.
Shimomura T, Mori K, Yasue K, Matsukawa A, Fukuokaya W, Yanagisawa T, Hata K, Murakami M, Koike Y, Miki J, Yamada H, Kimura T. Shimomura T, et al. Among authors: murakami m. Int J Clin Oncol. 2024 Feb;29(2):213-221. doi: 10.1007/s10147-023-02441-8. Epub 2023 Dec 16. Int J Clin Oncol. 2024. PMID: 38103156
Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
Urabe F, Muramoto K, Yanagisawa T, Fukuokaya W, Mori K, Tashiro K, Katsumi K, Takahashi H, Yoshihara K, Miyajima K, Imai Y, Iwatani K, Kayano S, Igarashi T, Murakami M, Tsuzuki S, Shimomura T, Yamada H, Miki J, Kimura T; JIKEI‐YAYOI Collaborative Group. Urabe F, et al. Among authors: murakami m. Int J Urol. 2024 Nov;31(11):1248-1255. doi: 10.1111/iju.15546. Epub 2024 Jul 19. Int J Urol. 2024. PMID: 39031448
Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study.
Urabe F, Imai Y, Goto Y, Tashiro K, Hashimoto M, Yoshihara K, Yamamoto S, Hara S, Miyajima K, Fukuokaya W, Enei Y, Iwatani K, Kayano S, Igarashi T, Aikawa K, Yanagisawa T, Kimura S, Tsuzuki S, Murakami M, Hata K, Shimomura T, Yamada H, Miki J, Kimura T. Urabe F, et al. Among authors: murakami m. Jpn J Clin Oncol. 2024 Nov 2;54(11):1208-1213. doi: 10.1093/jjco/hyae098. Jpn J Clin Oncol. 2024. PMID: 39037966
Presurgical immune-oncology/tyrosine kinase inhibitor combination therapy for renal cell carcinoma with a vena cava tumor thrombus: a single-institution case series.
Urabe F, Iwatani K, Hashimoto M, Suzuki H, Miyajima K, Murakami M, Tashiro K, Tsuzuki S, Furuta A, Sato S, Takahashi H, Kimura T. Urabe F, et al. Among authors: murakami m. Transl Androl Urol. 2023 Aug 31;12(8):1321-1325. doi: 10.21037/tau-23-203. Epub 2023 Aug 10. Transl Androl Urol. 2023. PMID: 37680224 Free PMC article.
Radiographic Progression at Castration-Resistant Prostate Cancer Diagnosis: A Prognostic Indicator of Metastatic Hormone-Sensitive Prostate Cancer.
Tashiro K, Kimura S, Tsuzuki S, Urabe F, Fukuokaya W, Mori K, Aikawa K, Murakami M, Sasaki H, Miki K, Miki J, Shimomura T, Yamada H, Hata K, Nishikawa H, Abe H, Watanabe K, Kimura T. Tashiro K, et al. Among authors: murakami m. Clin Genitourin Cancer. 2024 Jun;22(3):102075. doi: 10.1016/j.clgc.2024.102075. Epub 2024 Mar 21. Clin Genitourin Cancer. 2024. PMID: 38643665
Docetaxel versus androgen receptor signaling inhibitor (ARSI) against chemo-naïve castration-resistant prostate cancer (CRPC): propensity score matched analysis in real world.
Shimomura T, Mori K, Ito K, Yasue K, Matsukawa A, Fukuokaya W, Yanagisawa T, Hata K, Murakami M, Koike Y, Miki J, Yamada H, Kimura T. Shimomura T, et al. Among authors: murakami m. Int Urol Nephrol. 2024 Dec;56(12):3719-3725. doi: 10.1007/s11255-024-04116-3. Epub 2024 Jun 24. Int Urol Nephrol. 2024. PMID: 38913290
Optimizing prostate cancer detection in transition zone: an analysis of apparent diffusion coefficient values in prostate magnetic resonance imaging evaluation with Prostate Imaging Reporting and Data System (PI-RADS) assessment.
Imai Y, Urabe F, Sadakane I, Oguchi T, Iwatani K, Murakami M, Tashiro K, Aoki M, Sato S, Takahashi H, Tsuzuki S, Miki K, Kimura T. Imai Y, et al. Among authors: murakami m. Transl Androl Urol. 2024 Sep 30;13(9):2027-2035. doi: 10.21037/tau-24-235. Epub 2024 Sep 26. Transl Androl Urol. 2024. PMID: 39434761 Free PMC article.
5,829 results